Open, Non-controlled, Multicentre, First-in-man Study Using Escalating Doses of LFB-R603 in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia.
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2013
At a glance
- Drugs Ublituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 17 Jun 2013 Results will be presented at the 2013 European Hematology Association (EHA) Meeting according to a TG Therapeutics media release.
- 27 Apr 2012 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 27 Apr 2012 Actual patient number (33) added as reported by ClinicalTrials.gov.